Within, we have utilized the mouse cell line Myc-CaP [16] generated from the Hi-Myc transgenic mouse model of prostate cancer [17], which drives the expression of human c-Myc by the androgen receptor dependent rat probasin promoter, to assess the in vitro and in vivo anti-tumor activity of combination treatment with low dose HDACI panobinostat and the mTOR inhibitor everolimus. This evidence concerns the gene AR and neoplasm.